AstraZeneca registers Phase 3 trial of Symbicort Aerosphere in children
The study plans to enroll 216 participants aged 4 to <12 years and start on October 30, 2026. It plans to compare BFF MDI 80/4.8 μg 2 actuations BID to BD MDI 80 μg 2 actuations BID over 6 weeks to assess lung function and safety.
Primary source
ClinicalTrials.gov registry record, November 13, 2026
An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderate Persistent Asthma
Machine-summarized from the source above; not independently reported. How we use automation